ImmunoCellular Therapeutics Performance
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 3.36, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ImmunoCellular Therapeutics will likely underperform. ImmunoCellular Therapeutics right now retains a risk of 0.0%. Please check out ImmunoCellular Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and rate of daily change , to decide if ImmunoCellular Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ImmunoCellular Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, ImmunoCellular Therapeutics is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
ImmunoCellular |
ImmunoCellular Therapeutics Relative Risk vs. Return Landscape
If you would invest 47.00 in ImmunoCellular Therapeutics on September 15, 2024 and sell it today you would earn a total of 0.00 from holding ImmunoCellular Therapeutics or generate 0.0% return on investment over 90 days. ImmunoCellular Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than ImmunoCellular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmunoCellular Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmunoCellular Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as ImmunoCellular Therapeutics, and traders can use it to determine the average amount a ImmunoCellular Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| IMUC |
Based on monthly moving average ImmunoCellular Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmunoCellular Therapeutics by adding ImmunoCellular Therapeutics to a well-diversified portfolio.
ImmunoCellular Therapeutics Fundamentals Growth
ImmunoCellular Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of ImmunoCellular Therapeutics, and ImmunoCellular Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmunoCellular Pink Sheet performance.
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Cash And Equivalents | 933.15 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.78 M | ||||
| Debt To Equity | 0.39 % | ||||
| Book Value Per Share | (0.03) X | ||||
| Cash Flow From Operations | (2.31 M) | ||||
| Earnings Per Share | 28.91 X | ||||
| Total Asset | 30.08 M | ||||
| Retained Earnings | (74.14 M) | ||||
| Current Asset | 24.56 M | ||||
| Current Liabilities | 2.27 M | ||||
About ImmunoCellular Therapeutics Performance
By analyzing ImmunoCellular Therapeutics' fundamental ratios, stakeholders can gain valuable insights into ImmunoCellular Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImmunoCellular Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImmunoCellular Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey. Immunocellular Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.Things to note about ImmunoCellular Therapeutics performance evaluation
Checking the ongoing alerts about ImmunoCellular Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for ImmunoCellular Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmunoCellular Therapeutics is not yet fully synchronised with the market data | |
| ImmunoCellular Therapeutics has some characteristics of a very speculative penny stock | |
| ImmunoCellular Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ImmunoCellular Therapeutics currently holds about 933.15 K in cash with (2.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 95.0% of the company shares are held by company insiders |
- Analyzing ImmunoCellular Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmunoCellular Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining ImmunoCellular Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmunoCellular Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmunoCellular Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmunoCellular Therapeutics' pink sheet. These opinions can provide insight into ImmunoCellular Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |